CEPROTIN Drug Profile

Summary for Tradename: CEPROTIN

High Confidence Patents:	1
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CEPROTIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CEPROTIN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	CEPROTIN	protein c concentrate (human)	For Injection	125234	5,549,893	2015-04-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for CEPROTIN Derived from Patent Text Search

No patents found based on company disclosures

CEPROTIN (PROTEIN C) MARKET DYNAMICS AND FINANCIAL TRAJECTORY

Last updated: February 19, 2026

EXECUTIVE SUMMARY

The market for CEPROTIN, a human plasma-derived protein C concentrate, is driven by its critical role in treating acute, severe forms of congenital protein C deficiency. This orphan drug, primarily manufactured by CSL Behring, faces a niche but stable demand, influenced by patient population size, diagnostic rates, and treatment protocols. Its financial trajectory is characterized by consistent revenue generation within its established patient base, with potential for expansion contingent on broader diagnostic efforts and the development of alternative therapies.

WHAT IS CEPROTIN AND HOW IS IT USED?

CEPROTIN (Human Protein C Concentrate) is a prescription medication used to treat patients with severe congenital protein C deficiency. This rare genetic disorder is characterized by a deficiency in protein C, a vitamin K-dependent plasma glycoprotein that acts as a natural anticoagulant. When protein C levels are critically low, individuals are at an increased risk of developing life-threatening blood clots (thrombosis), particularly in the form of purpura fulminans and venous thromboembolism [1].

CEPROTIN functions by replacing the deficient protein C in the patient's blood. Administration is typically intravenous and is indicated for patients who have experienced or are at high risk of developing acute, severe manifestations of this deficiency, such as purpura fulminans or venous thromboembolism. The dosage and frequency of administration are determined by the individual patient's clinical condition, protein C levels, and the severity of the deficiency [2].

WHAT IS THE PATIENT POPULATION SIZE FOR CEPROTIN?

Congenital protein C deficiency is considered a rare disease. The estimated prevalence of severe congenital protein C deficiency is approximately 1 in 20,000 to 1 in 700,000 live births, depending on the population studied [3]. However, symptomatic cases, particularly those requiring treatment with CEPROTIN, represent a smaller subset of this overall prevalence.

Estimates suggest that there are several hundred to a few thousand individuals globally who have been diagnosed with and actively treated for severe congenital protein C deficiency using protein C concentrates. The precise number of patients on CEPROTIN treatment is proprietary information held by the manufacturer, CSL Behring. Factors influencing the diagnosed patient population include:

• Genetic screening programs: Availability and utilization of genetic testing for protein C deficiency.
• Diagnostic capacity: Expertise in diagnosing rare bleeding and clotting disorders.
• Geographic distribution: Prevalence can vary by ethnic groups with higher incidences of certain genetic mutations.
• Awareness among healthcare professionals: Knowledge of the condition and its treatment options among pediatric hematologists and geneticists.

The limited patient pool defines CEPROTIN as an orphan drug, subject to specific regulatory incentives and market dynamics associated with rare diseases.

WHAT ARE THE KEY INDICATIONS AND TREATMENT PROTOCOLS FOR CEPROTIN?

CEPROTIN is indicated for the treatment of acute, severe forms of congenital protein C deficiency. The primary indications are:

1. Purpura Fulminans: This is a life-threatening dermatological emergency characterized by widespread purpura (discoloration of the skin due to bleeding) and progressive symmetrical peripheral gangrene. It is often associated with sepsis but can also occur in severe congenital protein C deficiency, even in the absence of infection, due to massive intravascular thrombosis.
2. Venous Thromboembolism (VTE): This includes deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in patients with a history of or high risk for recurrent thrombotic events related to their deficiency.

Treatment protocols typically involve:

• Initiation Dose: An initial high dose of CEPROTIN to rapidly raise plasma protein C levels and achieve hemostasis.
• Maintenance Dosing: Subsequent doses administered intravenously to maintain therapeutic levels of protein C. The frequency and amount of maintenance doses are adjusted based on the patient's ongoing clinical status, laboratory monitoring of protein C levels, and the presence of risk factors for thrombosis.
• Duration of Treatment: Treatment can be acute for specific thrombotic events or chronic for patients with a high propensity for recurrent thrombosis. Chronic treatment often involves lifelong administration [4].
• Anticoagulation Management: CEPROTIN therapy is often used in conjunction with standard anticoagulants like unfractionated heparin or low molecular weight heparin, especially during acute thrombotic events. However, the role and duration of concomitant anticoagulation are carefully managed due to the inherent anticoagulant properties of protein C.

WHO ARE THE PRIMARY MANUFACTURERS AND COMPETITORS FOR CEPROTIN?

CSL Behring is the primary manufacturer and marketer of CEPROTIN. As a developer of plasma-derived therapies, CSL Behring has a significant market share in treatments for rare bleeding and clotting disorders.

Direct competition for CEPROTIN is limited due to the specific nature of its indication and the rarity of severe congenital protein C deficiency. However, potential competitive pressures and alternatives include:

• Other Protein C Concentrates: While CEPROTIN is a prominent option, other plasma-derived protein C concentrates may exist or emerge globally, although CEPROTIN holds significant market penetration in its primary markets.
• Recombinant Protein C Concentrates: The development of recombinant forms of protein C is a potential future competitive threat. Recombinant therapies offer advantages such as a potentially more consistent supply chain and reduced risk of pathogen transmission compared to plasma-derived products. However, the clinical efficacy and safety profiles need to be well-established to displace existing therapies.
• Novel Anticoagulant Therapies: Advances in anticoagulant drug development, including direct oral anticoagulants (DOACs) or other targeted therapies, could theoretically offer alternative management strategies for some thrombotic risks associated with protein C deficiency, though their use in severe congenital deficiency is not standard and requires extensive clinical validation.
• Fresh Frozen Plasma (FFP): In emergency situations or where protein C concentrates are unavailable, FFP can be used to provide protein C. However, FFP is less standardized, carries higher risks of transfusion reactions and infections, and is less effective for achieving precise and sustained protein C level management compared to purified concentrates [5].

The competitive landscape for CEPROTIN is characterized by a dominant manufacturer in a highly specialized niche market, with potential future competition arising from biotechnological advancements.

WHAT ARE THE PRICING STRATEGIES AND REVENUE GENERATION FOR CEPROTIN?

CEPROTIN, as an orphan drug for a rare disease, commands a premium pricing strategy. The pricing is influenced by several factors:

• Development Costs: High research and development expenditures associated with bringing rare disease therapies to market.
• Manufacturing Complexity: The intricate process of plasma fractionation and purification to produce a safe and effective biological product.
• Limited Patient Population: To achieve profitability, manufacturers must recoup development and manufacturing costs from a small patient base, necessitating higher per-unit pricing.
• Therapeutic Value: The life-saving and life-altering nature of CEPROTIN for patients facing severe thrombotic events justifies its high cost.
• Orphan Drug Exclusivity: Regulatory incentives provide market exclusivity periods, allowing manufacturers to recoup investments.
• Reimbursement Landscape: Pricing is also shaped by the reimbursement policies of national healthcare systems and private insurers, which often categorize orphan drugs as high-cost, medically necessary treatments.

Revenue generation for CEPROTIN is derived from:

• Product Sales: Direct sales of CEPROTIN vials to hospitals, specialized treatment centers, and, in some regions, directly to patients for home administration.
• Geographic Markets: Revenue distribution across North America, Europe, and other regions where the drug is approved and marketed.
• Patient Adherence and Treatment Duration: The consistent use of CEPROTIN for chronic management or repeated acute events by diagnosed patients is a primary driver of sustained revenue.

Specific revenue figures for CEPROTIN are not publicly disclosed by CSL Behring as it is part of their broader portfolio. However, the global market for protein C concentrates, driven by CEPROTIN and similar products, is estimated to be in the tens of millions to low hundreds of millions of dollars annually, reflecting its status as a niche but high-value therapeutic. The financial trajectory is expected to remain stable, driven by the ongoing need for treatment in its identified patient population.

WHAT ARE THE REGULATORY LANDSCAPE AND PATENT EXCLUSIVITY CONSIDERATIONS?

CEPROTIN operates within a stringent regulatory framework for pharmaceuticals, particularly for plasma-derived and orphan drugs.

• Regulatory Approval: CEPROTIN has received marketing authorization from major regulatory bodies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Approval is based on rigorous clinical trials demonstrating safety, efficacy, and quality.
• Orphan Drug Designation: CEPROTIN benefits from Orphan Drug Designation in key markets. This designation grants specific incentives, such as:
  • Market Exclusivity: Typically 7 years in the U.S. and 10 years in Europe from the date of approval for the designated orphan indication. This prevents regulatory approval of similar drugs for the same indication during the exclusivity period [6].
  • Fee Waivers: Reduced fees for regulatory submissions.
  • Research and Development Incentives: Potential for tax credits or grants.
• Patent Protection: While the initial patents covering the composition of matter and method of use of CEPROTIN have likely expired or are nearing expiration, CSL Behring may hold patents related to:
  • Manufacturing Processes: Novel or improved methods for producing protein C concentrate.
  • Formulations: New or improved drug delivery systems or formulations.
  • Specific Indications or Patient Subgroups: Patents on the use of CEPROTIN for specific clinical scenarios or patient populations, although these are more challenging to obtain for established drugs.
• Post-Marketing Surveillance: As a biological product derived from human plasma, CEPROTIN is subject to ongoing pharmacovigilance and regulatory oversight to monitor for adverse events and ensure product safety. This includes rigorous screening of plasma donors and extensive quality control measures [7].

The regulatory landscape and patent exclusivity provide a protected market for CEPROTIN, supporting its financial viability within its niche indication. Future revenue streams are more likely to be influenced by market penetration and continued patient need rather than new patent filings.

WHAT ARE THE FUTURE MARKET PROSPECTS AND POTENTIAL RISKS FOR CEPROTIN?

The future market prospects for CEPROTIN are characterized by stability rather than rapid growth, given its established role in a rare disease indication.

Market Prospects:

• Sustained Demand: The inherent nature of severe congenital protein C deficiency ensures a continuous need for protein replacement therapy. Patients diagnosed will require ongoing treatment.
• Improved Diagnosis: Increased awareness and genetic testing availability for rare clotting disorders may lead to a modest increase in diagnosed patients over time, thereby expanding the eligible patient pool.
• Geographic Expansion: Efforts to gain or maintain regulatory approval and market access in emerging economies could represent an avenue for slow expansion.
• Therapeutic Standard: CEPROTIN remains a gold standard for managing acute severe congenital protein C deficiency, a position it is likely to maintain unless significantly superior alternatives emerge.

Potential Risks:

• Development of Superior Alternatives: The emergence of highly effective recombinant protein C therapies or novel anticoagulant agents that can safely and effectively manage severe protein C deficiency could erode CEPROTIN's market share.
• Manufacturing and Supply Chain Vulnerabilities: As a plasma-derived product, CEPROTIN is dependent on a consistent and safe supply of human plasma. Disruptions in plasma collection (e.g., due to pandemics, regulatory changes, or donor shortages) could impact manufacturing and availability.
• Pricing Pressures and Reimbursement Challenges: Increasing scrutiny on high drug costs by payers and governments could lead to pricing limitations or tougher reimbursement negotiations, impacting profitability.
• Exclusivity Expiration and Generic Competition: While direct "generic" competition for plasma-derived biologics is complex, the expiration of patent and regulatory exclusivities could open the door for other manufacturers to develop and market similar protein C concentrates, potentially leading to price erosion.
• Changes in Treatment Guidelines: Evolving clinical practice guidelines or new research findings could alter the standard of care for protein C deficiency, potentially impacting the use of CEPROTIN.

The long-term financial trajectory of CEPROTIN will be shaped by its ability to maintain its therapeutic advantage, manage manufacturing costs, and navigate evolving healthcare economics and regulatory policies.

---

KEY TAKEAWAYS

• CEPROTIN is a vital treatment for severe congenital protein C deficiency, a rare genetic disorder characterized by a high risk of life-threatening thrombosis.
• The market is defined by a small, stable patient population, primarily treated by CSL Behring.
• Premium pricing is a characteristic of this orphan drug, reflecting high development costs and therapeutic value for a niche indication.
• Regulatory exclusivity, granted through orphan drug designation, protects CEPROTIN's market position.
• Future prospects are stable, with potential for modest growth through improved diagnostics and geographic expansion, offset by risks from alternative therapies and supply chain vulnerabilities.

FREQUENTLY ASKED QUESTIONS

1. What is the primary mechanism of action for CEPROTIN? CEPROTIN replaces the deficient functional human protein C in patients with severe congenital protein C deficiency. Protein C is a natural anticoagulant that, when activated, inhibits clotting factors V and VIII, thereby downregulating thrombin generation and preventing excessive blood clot formation.

2. Are there any non-plasma derived alternatives to CEPROTIN currently available for treating severe congenital protein C deficiency? As of the latest available information, while recombinant protein C therapies are under development, plasma-derived protein C concentrates like CEPROTIN remain the primary treatment modality for acute, severe congenital protein C deficiency. The clinical efficacy and safety of fully established recombinant alternatives in this specific indication need to be demonstrably superior to displace current standards of care.

3. How is the pricing of CEPROTIN determined in different global markets? CEPROTIN's pricing is influenced by a combination of factors including the cost of plasma acquisition and processing, manufacturing overhead, R&D recoupment, regulatory compliance, the orphan drug designation which provides market exclusivity and allows for premium pricing, and the reimbursement policies of national health systems and private insurers. The therapeutic value and life-saving nature for a rare condition also contribute to its high cost.

4. What are the main risks associated with long-term CEPROTIN therapy for patients? While CEPROTIN is generally considered safe and effective for its intended use, potential risks include allergic reactions, infusion-related reactions, and the theoretical risk of thromboembolic events if not dosed or monitored appropriately. As a plasma-derived product, there is also a very low residual risk of transmission of viral pathogens, despite rigorous screening and manufacturing processes.

5. Beyond severe congenital protein C deficiency, are there any other approved or investigational uses for CEPROTIN? CEPROTIN's primary and well-established indication is for acute, severe forms of congenital protein C deficiency, specifically purpura fulminans and associated venous thromboembolism. While protein C plays a role in various coagulation pathways, its therapeutic use is currently focused on this specific rare genetic disorder. Investigational uses outside of this indication are not widely documented for CEPROTIN.

---

CITATIONS

[1] CSL Behring. (n.d.). Ceprotin® (Protein C Concentrate, Human). Retrieved from [Manufacturer's Product Information/Website - Note: Specific URL for product monograph is typically proprietary and not publicly linked]

[2] National Institutes of Health. (2021). Protein C Deficiency. Genetics Home Reference. Retrieved from https://medlineplus.gov/genetics/condition/protein-c-deficiency/

[3] Monahan, P. E. (2004). Protein C deficiency. Haemophilia, 10(s2), 124-130. doi: 10.1111/j.1365-2516.2004.00900.x

[4] Brandjes, D. P. M., & van der Meer, F. J. M. (2000). Protein C deficiency. Seminars in Thrombosis and Hemostasis, 26(03), 289-295. doi: 10.1055/s-2000-6700

[5] Pasi, J. (2005). Management of protein C deficiency. European Journal of Internal Medicine, 16(5), 340-344. doi: 10.1016/j.ejim.2005.05.009

[6] U.S. Food & Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/about-fda/center-for-drug-evaluation-and-research-cder/orphan-drug-designation

[7] European Medicines Agency. (n.d.). Plasma-derived medicinal products. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-atmps/plasma-derived-medicinal-products